Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial

OBJECTIVE: The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-con...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:PLoS One
Egile Nagusiak: van Lelyveld, Steven F. L., Drylewicz, Julia, Krikke, Maaike, Veel, Ellen M., Otto, Sigrid A., Richter, Clemens, Soetekouw, Robin, Prins, Jan M., Brinkman, Kees, Mulder, Jan Willem, Kroon, Frank, Middel, Ananja, Symons, Jori, Wensing, Annemarie M. J., Nijhuis, Monique, Borghans, José A. M., Tesselaar, Kiki, Hoepelman, Andy I. M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2015
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514679/
https://ncbi.nlm.nih.gov/pubmed/26208341
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0132430
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak